When CLL patients temporarily stop their BTK inhibitor for a procedure, they can experience a "disease flare" mimicking relapse. It is critical for clinicians to recognize this phenomenon and not misinterpret it as true disease progression, as symptoms typically resolve upon restarting the medication.

Although continuous BTK inhibitors have the most prospective data for high-risk CLL (17p/TP53 mutations), some highly motivated patients still opt for fixed-duration treatment. This requires a detailed conversation where clinicians must explain the trade-off: achieving a treatment-free period may come at the cost of needing second-line therapy sooner.

Obinutuzumab infusions in CLL patients can cause severe reactions. A simple and effective mitigation strategy is to pre-treat the patient with a BTK inhibitor for as little as three days before the first infusion. This debulking effect significantly reduces infusion reaction risk and improves patient safety.

Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.

With highly effective CLL therapies, primary causes of mortality are now infections and secondary cancers from immunodeficiency. Research is now focusing on immune reconstitution after treatment, marking a pivotal shift towards managing long-term survivorship challenges beyond just controlling the leukemia itself.

While these drugs can cause neutropenia, it rarely leads to infections. Patients often feel clinically well despite low neutrophil counts. This 'paper problem' can usually be managed with G-CSF without needing to dose-reduce the primary CLL therapy.

In CLL, Progression-Free Survival (PFS) is a misleading metric for clinical benefit. Time-To-Next-Treatment (TTNT) is often much longer because patients can have biochemical or radiological progression by IWCLL criteria but remain asymptomatic and clinically well, delaying the need for a new therapy.

Improved T-cell function in CLL patients on BTK inhibitors is probably a result of the substantial reduction in disease burden, allowing the immune system to normalize. This effect is seen across different BTK inhibitors, challenging the older hypothesis that it was a specific off-target effect (ITK inhibition) of ibrutinib.

BTK inhibitors block B-cell receptor signaling, causing long-surviving CLL cells to undergo programmed cell death (apoptosis) from a lack of stimulation. The common side effects are due to off-target kinase inhibition, not the intended BTK blockade itself, which has negligible action on other cells.